Pulse Biosciences, Inc.
PLSE Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$52.66
KIRA · Stoqly’s AI analyst, in plain words
- Pulse Biosciences, Inc. had $0.4M of revenue in fiscal 2025.
- Its operating margin was −21,982.6%: of every 100 in sales, about −21,983 is left after running the business.
- Pulse Biosciences, Inc. lost $72.8M in fiscal 2025.
- Free cash flow was −$54.4M in fiscal 2025, −15,553.4% of revenue.
Market cap
—
P/E
—
Revenue
$0.4M
Net income
−$72.8M
Free cash flow
−$54.4M
Operating margin
−21,982.6%
Pulse Biosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−20,794.6%
No. It lost money last year.
Does profit turn into cash?
−15,553.4%
No. It spent more cash than it brought in.
What Pulse Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- PULSE BIOSCIENCES, INC.
- CIK
- 0001625101
Pulse Biosciences, Inc. · PLSE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.4M | $0.7M | $0.0M | $0.0M | $0.4M |
| Revenue growth | — | −50.6% | −100.0% | — | — |
| Gross margin | −38.8% | −1,606.3% | — | — | −54.0% |
| Operating margin | −4,443.9% | −8,293.9% | — | — | −21,982.6% |
| Net income | −$63.7M | −$58.5M | −$42.2M | −$53.6M | −$72.8M |
| Net margin | −4,489.4% | −8,357.9% | — | — | −20,794.6% |
| Diluted EPS | −$2.28 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$54.1M | −$47.0M | −$33.0M | −$36.3M | −$54.1M |
| Capital expenditure | $0.4M | $0.4M | $0.1M | $0.1M | $0.3M |
| Free cash flow | −$54.5M | −$47.4M | −$33.2M | −$36.5M | −$54.4M |
| FCF margin | −3,845.8% | −6,773.4% | — | — | −15,553.4% |
| Share count change | 20.3% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $44.4M | $61.1M | $44.4M | $118M | $80.7M |
| Shareholders' equity | $44.4M | −$2.2M | $44.4M | $115M | $80.7M |
| Current ratio | 6.8x | 10.4x | 6.8x | 11.9x | 10.5x |
| Returns and quality | |||||
| Return on equity | −189.3% | −277.9% | −200.5% | −67.3% | −74.4% |
| Return on tangible equity | −160.4% | — | −106.4% | −48.3% | −94.2% |
| Piotroski F-score | 4 | 3 | — | — | — |
| Altman Z'' | −18.3 | −12.6 | −16.1 | −0.2 | −10.1 |
Insiders bought, 12 months
$13.5M
3 insiders
Insiders sold, 12 months
$2.9M
1 insider
Of sales under plans
100%
$2.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pulse Biosciences, Inc. · PLSE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $52.66 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001625101). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.